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Objective: The role of thoracic surgery in patients with acquired immuno- 
deficiency syndrome (AIDS) continues to evolve. This review seeks to 
evaluate the outcome, morbidity, and mortality associated with video- 
assisted thoracoscopic surgery for empyema and pneumothorax in patients 
with AIDS. Methods: A retrospective r view was conducted of patients with 
AIDS in whom video-assisted thoracoscopic surgery was performed for 
empyema (group 1) or intractable pnenmothorax (group 2). Results: Twenty 
patients with AIDS (95% male, mean age 37.4 years, mean CD4 count 76 
cells/ml 3) underwent thoracoscopy. Surgery was performed for empyema 
(group 1) in 11 (55%) and intractable pnenmothorax (group 2) in nine 
(45%). Three patients (15%) died within 30 days of the operation. At mean 
follow-up (29 months), overall survival was 55%. For those who survived the 
hospitalization and died within the follow-up period (35.3%), mean survival 
time was 8.2 months (range 1 month to 27 months). In group 1, surgical 
procedures were performed after 8 days of chest ube drainage and included 
pleural debridement and mechanical pleurodesis (n = 11) along with lung 
biopsy (n = 6). Survivals at 30 days and 29 months' follow-up were 90.9% 
and 45.4%, respectively. In group 2, significantly depressed CD4 counts 
(average 33.2 cells/ml 3) were noted along with a more prolonged preoper- 
ative hospitalization (18.5 days) with 14.2 days spent with a chest tube 
before the operation. In this group, operative procedures included mechan l 
ical pleurodesis and talc poudrage (n = 9), bleb resection (n = 7), and lung 
biopsy (n = 1). Two deaths (22%) occurred within 30 days of the operation 
and survival at 29 months' follow-up was 66%. Conclusion: Video-assisted 
thoracoscopic surgery performed in patients with AIDS for the treatment of 
empyema and intractable pneumothorax is effective, can be performed with 
little operative morbidity and mortality, and is associated with acceptable 
long-term survival. Video-assisted thoracoscopic surgery is best performed 
soon after the diagnosis of intractable pneumothorax or empyema has been 
established. (J Thorac Cardiovasc Surg 1997;114:361-6) 
A S the frequency of acquired immunodeficiency syndrome (AIDS) has increased, so too has the 
role of surgery in the spectrum of therapy. Although 
thoracic ,;urgeons have been involved in the treat- 
ment of pulmonary complications of AIDS, the 
timing and utility of thoracic surgery in this popula- 
tion contiinues to develop?' 2 Pulmonary manifesta- 
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tions are common among patients with AIDS. Pneu- 
mocystis carinii pneumonia (PCP) is so closely 
associated with AIDS that its presence is diagnostic 
of the disease. PCP and other infectious agents have 
been linked to cavitary lesions in the lung paren- 
chyma, tissue necrosis, and pneumothorax. Empy- 
ema is a periodic complication of pneumonia in this 
population, necessitating definitive drainage with 
tube thoracostomy. Incompletely drained empyema 
requires urgery for relief of symptoms and resolu- 
tion of infection. Simple pneumothorax in patients 
with AIDS is most often treated by tube thoracos- 
tomy with success. However, intractable pneumo- 
thoraces refractory to multiple trials of closed 
suction have been identified. 3'4 These refractory 
pneumothoraces periodically require thoracic surgi- 
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cal intervention to facilitate the removal of chest 
tubes and discharge from the hospital. 
Video-assisted thoracoscopic surgery (VATS) has 
gained in popularity as an alternative to thoracot- 
omy in the treatment of pulmonary diseases. VATS 
has been used for early empyema, bleb resection, 
pleurodesis, pleural debridement for removal of 
empyema cavity debris, and talc poudrage. We have 
reviewed our experience with VATS in patients with 
AIDS to determine its role in the spectrum of 
therapy for the complications of AIDS. 
Methods 
A retrospective r view was conducted of patients with 
AIDS who underwent VATS between September 1991 
and April 1995. All inpatient records were reviewed and 
data regarding prehospital health status, demographics, 
comorbid factors, operative events, complications, and 
postoperative course were evaluated. Telephone contacts 
with all patients were conducted at various postoperative 
intervals. 
Patients were included for consideration if they had 
AIDS-defining illnesses or an absolute T-cell count of 
less than 200 cells/ml 3.Group 1 included patients under- 
going surgery for empyema. This diagnosis was based on 
computed tomography ofthe chest demonstrating anincom- 
pletely drained fluid collection from which bacterial spe- 
cies were isolated. Group 2 included patients with intrac- 
table pneumothorax. This was defined as pneumothorax 
without complete resolution after more than two trials of 
3 to 5 days of closed suction drainage. Intractable pneu- 
mothorax also described persistent air leak on chest ube 
suction for greater than 7 days. 
Thoracoscopic procedures were performed with the 
aid of general anesthesia n all patients, and a double- 
lumen endotracheal tube was used for single lung 
ventilation during the procedure. VATS was performed 
through three 10 mm ports (Bluntport, United States 
Surgical Corporation, Norwalk, Conn.) in a standard 
fashion. Pleural debridement is described as removal of 
pleura-based exudative and fibrinous material along 
with division of pleural adhesions and irrigation of the 
empyema cavity. Mechanical pleurodesis refers to the 
abrasion of the parietal pleura. Talc poudrage describes 
the instillation of sterilized talc powder into the tho- 
racic cavity. Parenchymal bullae were resected with 
Endo-GIA stapling equipment (United States Surgical 
Corporation). 
All data were evaluated with a Microsoft Excel (version 
4) statistical analysis package (Microsoft Corporation, 
Redmond, Wash.). Descriptive statistics and t testing were 
used for group evaluation and to examine intergroup 
relationships. A p value of < 0.05 was considered statis- 
tically significant. Data are presented as means unless 
otherwise specified. 
Results 
Twenty patients with AIDS who were undergoing 
VATS at St. Vincent's Hospital and Medical Center 
of New York were studied. Ninety-five percent of 
the patients were men (mean age 37.4 years). The 
source of human immunodeficiency virus (HIV) 
infection was identified as sexual contact by 65% of 
the patients and intravenous drug use by 25%. No 
source was provided in 10%. The average CD4 
count was 76 cells/ml 3. Previous medical history was 
significant for PCP (55%), Kaposi's sarcoma (30%), 
Mycobacterium intracellularae (10%), cytomegalovi- 
rus (25%), Cryptosporidium (5%), and toxoplasmo- 
sis (5%). Eleven patients (55%) had unilateral em- 
pyema (group 1). This diagnosis was based on 
computed tomography of the chest demonstrating 
an incompletely drained fluid collection from which 
bacterial species were isolated. In nine patients 
(45%) intractable pneumothorax (group 2) was di- 
agnosed. Intractable pneumothorax was defined as a 
recurrent pneumothorax after at least one trial of 
closed suction and waterseal drainage for 3 to 5 days 
for a spontaneous, primary pneumothorax. 
VATS was performed in all patients without 
event. No operative complications occurred and no 
conversions to thoracotomy were necessary. The 
operation was considered successful in all patients. 
The average length of hospitalization was 38 days 
and the time from admission until the operation was 
performed was 17.6 days. The average length of time 
with a chest tube was 9.2 days before the operation. 
Thirty-five percent required intensive care unit 
stays. Three patients (15%) died within 30 clays of 
the operation. No wound healing complications 
were noted. At a mean follow-up of 29 months, 
overall survival was 55%. For those who survived the 
hospitalization and died within the follow-up period 
(35.3%), mean survival time was 8.2 months (range 
1 to 27 months). 
Empyema. Demographic characteristics were 
similar when comparisons were made between pa- 
tients who had pneumothorax or empyema. Among 
patients undergoing surgery for empyema (group 1), 
the average CD4 count was 128 cells/ml 3. The 
average length of time with a chest tube before the 
operation was 8 days and after the operation, 3.4 
days. Surgical procedures included pleural debride- 
ment and mechanical pleurodesis (n = 11) and lung 
biopsy (n = 6). Pathologic evaluation of resected 
material revealed mixed bacterial species (n = 4), 
PCP (n = 2), Mycobacterium tuberculosis (n = 2), 
and no organisms (n = 3). 
Three patients were admitted to the intensive 
care unit for postoperative evaluation. One patient 
required continued mechanical ventilation and died 
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on postoperative day 23. Ten of 11 (90.9%) patients 
were discharged to their homes. Four patients died 
after discharge from the hospital (mean 243 days). 
Overall survival at 29 months' follow-up was 45.4%. 
No readmissions for thoracic surgical disease were 
necessary. 
Pneumothorax. Patients who had surgery for per- 
sistent pneumothorax (group 2) had significantly 
depressed CD4 counts (average 33.2 cells/ml3). A 
prolonged[ preoperative hospital admission was 
noted in this group (18.5 days), with a mean of 14.2 
days spent with a chest tube before the operation. 
Seven patients had at least two trials of waterseal 
drainage before the operation. Three of nine pa- 
tients (33%) had the chest tube removed and re- 
placed for recurrence of pneumothorax before the 
operation. 
VATS was used to perform mechanical or talc 
pleurodesis, or both (n = 9), bleb resection (n = 7), 
and lung biopsy (n = 1). On average, two chest ubes 
were placed at the completion of the operation, and 
the last of these tubes remained in place for a mean 
of 4.1 days after the operation. Pathologic condi- 
tions included PCP (n = 7), cytomegalovirus (n = 
1), and Kaposi's sarcoma (n = 1). 
Four patients were admitted to the intensive care 
unit after the operation (44%) for respiratory insuf- 
ficiency resulting in two operative deaths (22%, 
30-day mortality). Two patients died within 12 
months of hospital discharge with a calculated sur- 
vival of 6,6% at 29 months' follow-up. No recurrent 
pneumothoraces were identified at follow-up. 
Discussien 
The role of the surgeon in dealing with the 
complications of HIV/AIDS continues to evolve. 
With growing experience the surgical community 
has identified many pathologic entities that are 
either reversible or ameliorated by surgery. One of 
the earlie, st reports of thoracic surgery in this group 
of patients evaluated thoracic surgical procedures 
(tracheostomy, repair of air leaks, mediastinoscopy, 
lobectomy, lung biopsy, and esophagogastrectomy) 
performed uring 49 operationsJ This early evalu- 
ation recognized that certain thoracic procedures 
represented futile care whereas others provided 
effective symptomatic relief with limited morbidity. 
In patients with AIDS the complications of pneu- 
monia periodically require surgical intervention. 
These complications include complex pleural effu- 
sion, empyema, and pneumothorax. The operations 
typically are performed on an emergency basis and 
have not lent themselves to critical review. Thora- 
cotomy for pneumothorax or empyema has been 
advocated by some, 1whereas others have suggested 
that minimally invasive surgery for patients with 
AIDS may be more suitable. 2 In either case sparse 
data exist to support he role of surgery and no large 
surgical series has demonstrated the proper indica- 
tions, predicted outcomes, and risk/benefit ratio of 
thoracic surgery in the patient with AIDS. 
Coker and associates 3 identified 87 patients with 
AIDS-related PCP, among whom 16 pneumothora- 
ces were identified. Pneumothorax was linked to 
aerosolized pentamidine (for early treatment of 
PCP) and PCP alone in 58% and 83% of cases, 
respectively. In another series 4aerosolized pentam- 
idine was associated with spontaneous pneumotho- 
rax in patients with AIDS. Pneumothorax was iden- 
tified in 12 of 327 patients undergoing this therapy. 
Of these, 75% had active PCP, 83% required chest 
tube insertion, and 50% died. A retrospective r - 
view s found that the incidence of pneumothorax in 
patients with PCP was 8 of 89 (9%) compared to 0% 
in patients without PCP. Prospective analysis 6 of 
patients with AIDS determined the rate of pneumo- 
thorax to be 20 of 1030 patients (2%). Of these, 19 
had compelling evidence of PCP infection. Aerosol- 
ized pentamidine demonstrated a 17.6% increase in 
relative risk and PCP a 14.5% increased risk. The 
mortality rate associated with pneumothorax was 
10%. Gerein and coworkers 7 described 22 patients 
with pneumothorax, of whom 17 died within the 
time frame of the study (average 147 days from 
initial pneumothorax therapy). In a similar report, 
23 of 40 patients with pneumothorax died within 8 
weeks of pneumothorax. 8 An important subset of 
patients described by Byrnes, Brevig, and Yeoh 9 is 
the group in whom pneumothorax developed while 
the patients were being supported by a ventilator; 
their mortality rate was 92%. 
The pathophysiology of PCP-related pneumotho- 
rax has been suggested from analysis of wedge 
resections of autopsy specimens. I° Tissue invasion 
with PCP and regional necrosis with cavitation was 
found in seven of eight patients with pneumothorax. 
Others 8 have found PCP-infected lung specimens 
that demonstrated an interstitial inflammatory pro- 
cess with subpleural necrosis and bullous change. 
Spontaneous rupture of such necrotic lung tissue is 
the suggested pathophysiology of pneumothorax. 
Tissue necrosis is likely related to poor tissue heal- 
ing and refractory pneumothorax or air leak after 
conservative management. 
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Despite the poor survival noted in early studies, 
some have reported reasonable improvements in
outcomes after operations for pneumothorax. 
Gerein and associates 7 described the results of eight 
of 22 patients with pneumothorax who underwent 
surgical procedures for resolution of pneumothorax. 
Open pleurectomy was performed in six with no 
recurrence noted. Although little follow-up was 
provided, a treatment algorithm was offered that 
emphasizes surgical pleurectomy for unsuccessful 
tube thoracostomy use or bilateral disease. This 
radical surgical approach as been reinforced by a 
case report 11 that advocated median sternotomy 
for bilateral pneumothorax. In the largest series 
of surgical intervention for AIDS-related thoracic 
disease, Horowitz and Olive 12 reported on seven 
patients undergoing eight open procedures for 
AIDS-associated pneumothorax. In this series, pos- 
terolateral thoracotomy was performed in five pa- 
tients and sternotomy in two. No operative deaths 
were noted and mean time from operation until 
discharge was 13 days. Three patients died between 
4 and 8 months after the operation. 
The surgical community has increasingly applied 
minimally invasive technology to common thoracic 
procedures. Daniel, Tribble, and Rodgers 13 de- 
scribed the use of VATS and talc poudrage in 40 
patients. None of these patients had HIV infection 
or AIDS. A 95% success rate was noted in 20 
patients with spontaneous pneumothorax. Of 20 
patients with intractable pleural effusions, 90% had 
successful outcomes. Minimally invasive surgery has 
particular advantages in those in whom the risk of 
thoracotomy is high. Despite the growing accep- 
tance of this technique in coordination with bleb 
resection and pleurodesis, a4only scattered reports 
have described VATS in HIV/AIDS-related pneu- 
mothorax. Tunon-de-Lara and coworkers ~5 describe 
a single case of talc pleurodesis after pleuroscopic 
examination i a patient with AIDS. This patient 
died within 2 months of the operation. The only 
additional report ~6 detailed the thoracoscopic instil- 
lation of talc in a single patient with pneumothorax. 
No follow-up was provided. 
The three phases of empyema development (ex- 
udative, fibrinopurulent, and organizing) have been 
well described ~7 and in large part determine the 
feasibility of surgical techniques for this disease. The 
early exudative phase of empyema is adequately 
treated with tube thoracostomy drainage. The fi- 
brinopurulent stage of empyema most often re- 
quires surgical intervention to allow for resolution 
of infection, clearance of exudative and fibrinous 
debris, and complete reexpansion ofthe lung. In the 
organized phase of empyema development, a thick 
pleural "cortex" may trap the lung and most often 
requires a thoracotomy for removal. Although sev- 
eral authors 18-2° have evaluated the role of thora- 
coscopy for the treatment of empyema, the role of 
VATS for patients with AIDS has not heretofore 
been described. 
This report details the largest series, to date, of 
thoracoscopic surgery in patients with AIDS. Our 
institutional experience has generated an aggressive 
treatment algorithm (Fig. 1) for the management of 
this patient population. Patients with intractable 
pneumothorax (pneumothorax without resolution 
after at least one trial [3 to 5 days] of closed suction 
drainage) undergo thoracoscopic pleurodesis, resec- 
tion of blebs when appropriate, and talc poudrage. 
Similarly, incompletely drained empyema is treated 
with surgery as early as that diagnosis is established 
and the patient's condition can be stabilized. For 
empyema, this time frame is usually 7 to 10 days 
after identification and once incomplete drainage 
from the chest ube has been recognized. Computed 
tomography of the chest is most often performed to 
assess the degree, location, and chronicity of the 
empyema cavity. For VATS to be performed ade- 
quately in patients with empyema, it is imperative 
that the operation be done before the development 
of a thick pleural "cortex" or significant lung trap- 
ping. The use of VATS for pleural debridement 
adequately allows for complete resolution of infec- 
tion) s-2° Pleural debridement refers to the removal 
of fibrinous exudate and adhesions that form in the 
empyema cavity along with the resection of pleural 
"membranes" that might prevent complete reinfla- 
tion of the lung. 2° The ability to perform adequate 
decortication of a more organized empyema is lim- 
ited by the thoracoscopic approach and associated 
with a higher likelihood of conversion to thoracot- 
omy. ls-20 
Our results indicate that VATS can be applied 
with successful outcomes for both intractable pneu- 
mothorax and empyema. VATS is well tolerated by 
this patient population (30-day survival for group 1 
was 91% and for group 2, 78%). A better than 
expected rate of survival was noted at 2 years' 
follow-up (group 1, 45%; group 2, 66%), especially 
when considering the extreme level of immunosup- 
pression oted in this review. This is more signifi- 
cant when considering that most of these patients 
would be unable to leave the hospital (because of 
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........ : ...P!e urOdesis ._ 
Early thoracoscopy 
Pleurodesis 
Bleb resection if indicated 
Talc poudrage 
Fig. 1. Algorithm for the use of thoracoscopy in the treatment ofpatients with AIDS. 
ongoing Jinfection or chest tubes necessitating suc- 
tion) unless urgical intervention was applied. Chest 
tubes are removed within 3 to 4 days after the 
operation. This is contrasted to the prolonged peri- 
ods of time with chest tubes before the operation 
(group 1, 8 days; group 2, 14 days). 
We have identified few predictors of survival after 
thoracoscopic surgery; however, patients in whom 
VATS is performed for empyema tended to require 
fewer intensive care unit admissions and were dis- 
charged from the hospital more rapidly if the oper- 
ation was performed less than 7 days after chest ube 
insertion. As well, patients in whom VATS was 
performed for pneumothorax tended to require 
fewer days in the hospital after the operation and to 
have improved outcomes when the operation was 
performed after the first trial of closed suction 
drainage rather than after repeated trials. These 
relationships did not achieve statistical significance. 
Lower CD4 counts appeared to be linked to wors- 
ened postoperative survival but were not indepen- 
dent, predictive variables when evaluating for surgi- 
cal risk. Indeed, we were surprised by the profound 
level of immunosuppression dentified in patients 
undergoing operations for pneumothorax (group 2) 
and the low level of postoperative morbidity and 
mortality in this group. 
Several nonsurgical alternatives exist for the 
treatment of patients with intractable pneumotho- 
rax and empyema. 21 To avoid operative interven- 
tions, some have suggested leaving chest tubes in 
place for more prolonged periods, attaching one- 
way (Heimlich) valves for those with persistent air 
leaks, or applying bedside chemical pleurodesis. For  
empyema, enzymatic debridement has been offered 
as an alternative therapy. In general, the least 
morbid and most effective therapeutic ntervention 
should be considered in all patients with pulmonary 
disease. In patients with AIDS this is complicated by 
associated comorbid disease and the higher than 
expected 30-day mortality identified in this study. 
However, it has been our experience that for both 
intractable pneumothorax nd pleural effusion/em- 
pyema, early surgical intervention using the thora- 
coscope is the least morbid and most effective 
available therapy. Although this study did not com- 
pare operative and nonoperative therapy, such an 
evaluation would be helpful. It is our impression 
that the mortality involved in thoracoscopy has less 
to do with the procedure than with the late stage of 
presentation of these complications of AIDS. A 
further challenge is to identify prognostic indicators 
of poor outcome to allow better patient selection for 
surgical therapy. For example, patients who re- 
quired mechanical ventilation for associated respi- 
ratory insufficiency were not offered VATS interven- 
tion. 
Although no direct comparisons between thora- 
coscopic surgery and alternative therapy have been 
reported, we have observed that surgery is the more 
definitive and consistently successful therapy. Tra- 
chiotis and associates 21 have reported good out- 
comes using an algorithm that emphasizes conser- 
vative management (Heimlich valves) over surgical 
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therapy for intractable pneumothorax in patients 
with AIDS. Although these patients may leave the 
hospital, there are compelling reasons 22 to avoid 
Heimlich valves. Leaving chest tubes with open 
drainage in patients with AIDS may pose a health 
risk to the patient and the community. 22 The risk of 
empyema with persistent chest tube and Heimlich 
valve may be higher than expected. Most important, 
unlike Heimlich valves, thoracoscopy offers a chance 
for these chronically ill patients to leave the hospital 
and live their remaining days without chest tubes. 
We do not routinely use talc slurry for pneumotho- 
rax because experience has shown us that PCP- 
related pneumothorax does not consistently respond 
to this therapy. Last, enzymatic debridement of 
loculations in early empyema may have a role in the 
spectrum of therapy. However, our experience sug- 
gests that, as in patients without HIV infection, early 
and complete reinflation of the lung and oblitera- 
tion of the infected pleural space remains the best 
available therapy. For these reasons the suggested 
algorithm emphasizes early thoracoscopic manage- 
ment in patients with intractable pneumothorax or 
empyema. 
Thoracoscopy for the complications of AIDS- 
related pulmonary manifestations i well tolerated, 
adequately resolves the pathologic ondition, and is 
associated with favorable outcomes. Only by evalu- 
ating the utility of surgical interventions can the 
medical community adequately serve its patients. 
Thoracoscopy for intractable pneumothorax and 
empyema has a clear role in the spectrum of AIDS. 
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